- Home
- CING vs BRTX Comparison
CING vs BRTX Comparison
Compare CING & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- BRTX
- Stock Information
- Founded
- CING 2012
- BRTX 1997
- Country
- CING United States
- BRTX United States
- Employees
- CING N/A
- BRTX N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- BRTX Managed Health Care
- Sector
- CING Health Care
- BRTX Health Care
- Exchange
- CING Nasdaq
- BRTX Nasdaq
- Market Cap
- CING 13.1M
- BRTX 11.2M
- IPO Year
- CING 2021
- BRTX N/A
- Fundamental
- Price
- CING $4.16
- BRTX $1.85
- Analyst Decision
- CING Strong Buy
- BRTX Strong Buy
- Analyst Count
- CING 3
- BRTX 1
- Target Price
- CING $16.00
- BRTX $18.00
- AVG Volume (30 Days)
- CING 78.2K
- BRTX 48.0K
- Earning Date
- CING 05-07-2025
- BRTX 03-27-2025
- Dividend Yield
- CING N/A
- BRTX N/A
- EPS Growth
- CING N/A
- BRTX N/A
- EPS
- CING N/A
- BRTX N/A
- Revenue
- CING N/A
- BRTX $401,000.00
- Revenue This Year
- CING $82.10
- BRTX $482.76
- Revenue Next Year
- CING N/A
- BRTX $212.24
- P/E Ratio
- CING N/A
- BRTX N/A
- Revenue Growth
- CING N/A
- BRTX 175.03
- 52 Week Low
- CING $1.80
- BRTX $1.03
- 52 Week High
- CING $20.83
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- CING 52.65
- BRTX 53.36
- Support Level
- CING $3.95
- BRTX $1.72
- Resistance Level
- CING $4.44
- BRTX $1.85
- Average True Range (ATR)
- CING 0.27
- BRTX 0.13
- MACD
- CING 0.07
- BRTX 0.02
- Stochastic Oscillator
- CING 66.89
- BRTX 50.98
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.